Drug Trial Radar · NCT03627767
Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects
Last checked: Nov 19, 2026Latest source record: Sep 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,235
Actual
Start
Jun 11, 2018
Primary completion
Sep 2, 2020
Study completion Oct 7, 2020
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken orally once daily (QD) will be identified and randomized in a double-blind manner to receive 200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible patients will have the option to enter a long-term extension study after completing the initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment.
Conditions
- Dermatitis
- Dermatitis, Atopic
- Eczema
- Skin Diseases
- Skin Diseases, Genetic
- Genetic Diseases, Inborn
- Skin Diseases, Eczematous
- Hypersensitivity
- Hypersensitivity, Immediate
- Immune System Diseases
Interventions
PF-04965842 100 mgDrug
PF-04965842 100 mg, administered as two tablets to be taken orally once daily for 40 weeks
PF-04965842 200 mgDrug
PF-04965842 200 mg, administered as two tablets to be taken orally once daily for 40 weeks
PlaceboDrug
Placebo, administered as two tablets to be taken orally once daily for 40 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Loss of Response: Double-blind (DB) PeriodTime frame: From Day 1 of up to Week 40 of double blind period
- Time to Loss of Response: Double-blind PeriodTime frame: From date of first dose of randomized treatment until the last dose of randomized treatment (if not entered rescue) or first day of rescue treatment (if entered rescue) (maximum up to Week 40, visit window was extended +/- 45 Days due to COVID 19)
Locations
235 sites in 21 countries. Site status is shown where the registry gives one.
Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama
University of Alabama at Birmingham, Dermatology at the Whitaker Clinic
Birmingham, Alabama
Clinical Research Center of Alabama, LLC
Birmingham, Alabama
Tien Q Nguyen MD Inc dba First OC Dermatology
Fountain Valley, California
Center for Dermatology Clinical Research, Inc.
Fremont, California
Beach Allergy and Asthma Specialty Group, A Medical Corporation
Long Beach, California
Dermatology Specialists, Inc.
Oceanside, California
University of California San Diego
San Diego, California
San Luis Dermatology and Laser Clinic
San Luis Obispo, California
Southern California Dermatology, Inc.
Santa Ana, California
Mosaic Dermatology
Santa Monica, California
Bay Pines VAHCS
Bay Pines, Florida
Skin Care Research, LLC
Boca Raton, Florida
Skin Research Institute
Coral Gables, Florida
Baumann Cosmetic and Research Institute
Miami, Florida
Park Avenue Dermatology
Orange Park, Florida
USF Asthma, Allergy & Immunology Clinical Research Unit
Tampa, Florida
Emory University
Atlanta, Georgia
Dermatologic Surgery Specialists, PC
Macon, Georgia
Midwest Allergy Sinus Asthma, SC
Normal, Illinois
NorthShore University HealthSystem Dermatology Clinical Trials Unit
Skokie, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
Ds Research
New Albany, Indiana
The Indiana Clinical Trials Center
Plainfield, Indiana
Kansas City Dermatology, P.A.
Overland Park, Kansas
DXP Imaging
Louisville, Kentucky
Skin Sciences PLLC
Louisville, Kentucky
Qualmedica Research, LLC
Owensboro, Kentucky
Owensboro Dermatology Associates
Owensboro, Kentucky
Meridian Clinical Research, LLC
Baton Rouge, Louisiana
Tulane University Health Sciences Center
New Orleans, Louisiana
Tufts Medical Center
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
MediSearch Clinical Trials
Saint Joseph, Missouri
Saint Louis University Dermatology
St Louis, Missouri
Forest Hills Dermatology Group
Kew Gardens, New York
Juva Skin and Laser Center
New York, New York
UR Dermatology at College Town
Rochester, New York
M3 - Wake Research, Inc.
Raleigh, North Carolina
Bexley Dermatology Research
Bexley, Ohio
Showing 40 of 235 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.